Design of the study aimed to assess the maximum tolerable dose of a new drug is best described as:
## Core Concept
The question assesses understanding of clinical trial design types, specifically focusing on the study aimed at determining the maximum tolerable dose of a new drug. This concept falls under the category of **Phase I clinical trials**, which are primarily concerned with evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug.
## Why the Correct Answer is Right
The correct answer, **Phase I**, is aimed at finding the maximum tolerated dose (MTD) of a new drug. This phase involves a small number of participants and focuses on assessing the drug's safety, tolerability, and pharmacokinetics. The MTD is the highest dose that can be given to patients without causing unacceptable side effects. This phase often employs a dose escalation design, where participants are given increasingly higher doses of the drug until the MTD is identified.
## Why Each Wrong Option is Incorrect
- **Option A: Phase II** - This phase is focused on evaluating the efficacy of the drug, as well as continuing to assess its safety. It involves a larger number of participants than Phase I and aims to determine the effectiveness of the drug in treating a specific condition.
- **Option B: Phase III** - This phase involves a much larger number of participants and aims to confirm efficacy, monitor side effects, compare the drug to commonly used treatments, and collect information that will allow the experimental drug to be used safely.
- **Option C: Phase IV (Post-marketing surveillance)** - This phase involves studies performed after a drug has received permission to be sold by the pertinent regulatory authorities. The main goal is to monitor the drug's long-term effects in a general population.
## Clinical Pearl / High-Yield Fact
A key point to remember is that **Phase I trials are primarily about safety and finding the MTD**, not about proving the drug's efficacy. These trials often involve a small number of healthy volunteers or patients and use a dose escalation strategy to find the MTD.
## Correct Answer: C. Phase I.